About Us
Sensifree is focused on helping physicians in hospitals to do their work better. In developing our products, we work closely with clinicians on the best ways to provide them with the information they need, while simplifying their work processes and reducing workload.
Our innovative technology facilitates easy to use solutions, supporting clinician’s decision making towards a better patient care.
We, like our customers, value affordable, easy to use solutions. We made these standard design objectives in all of our products.
What we do
Our first product implements Sensifree’s patent pending, novel technology for continuous, non-invasive blood pressure (cNIBP) monitoring. This product uses the ubiquitous, low-cost fingertip SpO2 sensor to provide functionality that otherwise requires either invasive or very expensive solutions. Our aim is to extend cNIBP to larger group of patients and make it the new standard of care in hospital BP monitoring.
A Paradigm Shift in Blood Pressure Monitoring
Sensifree’s vision is to create a paradigm shift in the way blood pressure is monitored. Continuous reading of blood pressure will increase patient safety and help to improve the medical outcome.
The merits of continuous blood pressure (BP) monitoring have long been established, with arterial lines commonly accepted as the gold standard for it. However, the invasive nature of arterial line, the relative complexity of the procedure and associated complications, limit its use to cases where these shortcomings are justified.
Arterial lines are mostly used with acute patients in intensive care units (ICU), high dependency units and in anaesthetized patients undergoing surgical procedures. For less acute patients, the associated risk, complexity, and management of cannulated patients often outweigh the benefits of invasive continuous BP monitoring.
In most cases, BP is still monitored using a technology that hasn’t changed much for more than a century – the inflatable BP cuff. Even when used in automatic monitors, it provides only intermittent readings and frequent cuff measurements are not well tolerated by patients.
Numerous studies have shown the shortcomings of intermittent BP readings, both in acute care settings and in the general wards, resulting in missing out events of high or low BP. These events, going unnoticed by medical personnel, manifest themselves in serious complications and even death.
A low risk, low-cost, easy to use method for continuous, non-invasive BP (cNIBP) monitoring would therefore have a great value in the treatment of hospitalized patients, going through the various stages of their admission.
Our products are well tolerated by patients and affordable to the healthcare provider. We are initially targeting in-hospital applications in general & surgical wards, and critical care units. Our roadmap includes monitoring of additional vital signs to provide a broader view on patients’ condition. We further plan to expand beyond the hospital boundaries to offer remote monitoring of patients discharged from the hospital and patients with certain chronic conditions, such as hypertension, end stage renal disease and preeclampsia.
A new standard of care in hospital BP monitoring
The SentiCor product family extends continuous blood pressure monitoring to larger patient populations through the different stages of their admission. Clinicians and patients can now benefit from the advantages of arterial line monitoring, without the associated risk, cost and complexity.
SentiCor monitors rely on Sensifree’s patent pending technology of analyzing the waveshape of a PPG signal. Our technology is based on the physiology of the human cardiovascular system and the physics of fluid dynamics in the arteries. We have implemented a unique approach of dynamic biomechanical modeling of the cardiovascular system for tracking changes in blood pressure. All SentiCor monitors provide continuous reading of systolic, diastolic and mean arterial pressure (MAP) values, as well as trend lines of BP values, all in a compact form factor and at affordable price.
Top reasons for choosing a SentiCor monitor:
- Affordable, continuous & non-invasive BP monitoring; fits standard care practices
- Easy to use by a nurse or technician
- Standard EMR interface
- Choice of sensor – use the existing patient monitor SpO2 sensor or Sensifree’s optimized, low-cost, disposable sensor
- Flexible pricing models at a fraction of alternative solutions’ cost
Product is available in select markets
The SentiCor product family extends continuous blood pressure monitoring to larger patient populations through the different stages of their admission. Clinicians and patients can now benefit from the advantages of arterial line monitoring, without the associated risk, cost and complexity.
SentiCor monitors rely on Sensifree’s patent pending technology of analyzing the waveshape of a PPG signal. Our technology is based on the physiology of the human cardiovascular system and the physics of fluid dynamics in the arteries. We have implemented a unique approach of dynamic biomechanical modeling of the cardiovascular system for tracking changes in blood pressure. All SentiCor monitors provide continuous reading of systolic, diastolic and mean arterial pressure (MAP) values, as well as trend lines of BP values, all in a compact form factor and at affordable price.
Top reasons for choosing a SentiCor monitor:
- Affordable, continuous & non-invasive BP monitoring; fits standard care practices
- Easy to use by a nurse or technician
- Standard EMR interface
- Choice of sensor – use the existing patient monitor SpO2 sensor or Sensifree’s optimized, low-cost, disposable sensor
- Flexible pricing models at a fraction of alternative solutions’ cost
Sensifree?s Platform Technology
Our proprietary, patent pending technology platform comprises of two main elements:
1. Unique technology, based on the use of standard optical (PPG) sensors
2. Advanced algorithmic layer to calculate and track blood pressure
Our sensor features red and infra-red wavelengths that track blood volume inside the pulsating blood vessel and then constructing a unique signal, originating at the index finger. The result is a continuous waveform that is proportional to the arterial pressure wave.
We then apply our proprietary algorithms, based on biomechanical modeling of the cardiovascular system to extract and track systolic and diastolic blood pressures, as well as mean arterial pressure (MAP).
Key benefits of our Platform:
- Noninvasive & Continuous waveform trace display
- Real time monitoring and tracking of blood pressure values
(MAP, systolic and diastolic) - Early detection and alert of condition deterioration
- Based on analytic cardiovascular model, not relying
on heuristic parameters database - Simple sensor positioning
- Affordable and reliable design
Sensifree’s Platform Breadth of Parameters
Blood Pressure (BP) &
Mean Arterial Pressure (MAP)
Heart Rate (HR) &
Heart Rate Variability (HRV)
Cardiac Output (CO)
Respiration Rate (RR)
Vascular Resistance
Pulse Pressure (PP) &
Pulse Pressure Variability (PPV)
Stroke Volume (SV) &
Stroke Volume Variability (SVV)
Clinically Validated Sensor Technology
We analyzed data from more than 250 patients with over 1.6 million data points with reference to arterial line, the gold standard.
The comparison demonstrated that our accuracy results are within the FDA requirements for blood pressure monitors, according to the ISO81060-2 standard.
News
Aug 31
2022
KFAR SABA, Israel and SANTA CLARA, Calif., Aug. 31, 2022 (PRNewswire) — Sensifree LTD, a world innovator in advanced hemodynamic monitoring (“Sensifree”), received CE certificate for SentiCor-100® in compliance with the new EU MDR. SentiCor-100® is the world’s first PPG based Continuous Non-Invasive Blood Pressure (cNIBP) monitoring device approved for hospital use.
“This is an important landmark in our journey to set a new standard of care in hospital blood pressure monitoring” said Eran Agmon, Chief Executive Officer and co-founder of Sensifree. “The use of the low-cost, safe and trusted PPG sensor truly opens up the door for widespread deployment of cNIBP monitors in hospitals.”
Sensifree also announced today on new OEM product release – SentiCor-X. Sensifree’s clinically validated, patented innovative monitoring technology is now offered for integration into patient monitors and other medical devices that require advanced BP monitoring capabilities, packed in a small form factor and with standard interfaces.
Eran Agmon commented on this product release: “we see OEM customers as an important sales channel. Our technology lends itself for simple integration into ordinary patient monitors, allowing manufacturers to make their products stand out in the market. We are actively engaged with our business partners on bringing such products to the market in the very near future.”
Feb 8
2022
Petach-Tikva, Israel and Cupertino, California (Feb. 8, 2022) – (PRNewswire) – Sensifree LTD, a medical device company developing advanced patient monitoring solutions (“Sensifree”), today announced the launch of a joint development program supported by the BIRD Foundation, with Cleveland Clinic.
Sensifree will develop the next generation of a device for non-invasive monitoring of blood pressure and other hemodynamic parameters. The product is intended for professional use and is expected to improve quality of care, patient safety and medical outcome of hospitalized patients. Cleveland Clinic will test and clinically validate the device.
“We are excited and proud to win this vote of confidence by the BIRD foundation,” said Eran Agmon, Chief Executive Officer and co-founder of Sensifree. “Cleveland Clinic’s experience in this subject matter and high academic standards are a true asset for moving the science forward.”
“A continuous non-invasive blood pressure monitor would be valuable for clinicians. Blood pressure monitoring is a focus for the department of Outcome Research because hypotension is common and potentially serious.” said Prof. Daniel Sessler, Director of the department of Outcome Research at the Cleveland Clinic.
Aug 11
2020
Petach-Tikva, Israel and Cupertino, Calif. (August 11, 2020) – (PRNewswire) – Sensifree LTD, a medical device company developing advanced patient monitoring solutions (“Sensifree”), today announced that Sensifree and Dreamtech Co., LTD (“Dreamtech”) have launched a joint development program supported by the Korea-Israel Research and Development Foundation (KORIL-RDF), to develop an innovative non-invasive blood pressure and other vital signs monitoring solutions for professional use.
The purpose of the grant is to develop commercial, paradigm-shifting products for continuous monitoring of blood pressure and additional vital signs in hospitals and other clinical settings, using Sensifree’s innovative, proprietary technology and Dreamtech’s commercialization capabilities. These products will help to improve quality of care, patient safety and medical outcome.
“The launch of this program is a major milestone as we move towards regulatory clearance and market entry,” said Eran Agmon, Chief Executive Officer and co-founder of Sensifree. “Dreamtech’s design and production capabilities are a great addition to our efforts of bringing products to the market. We thank Dreamtech and KORIL-RDF for providing development and manufacturing expertise and financial support necessary for our vision to improve clinicians practice and patient’s medical outcome.”
“We believe that this joint effort will provide commercially and clinically viable solutions. We are impressed with Sensifree’s technology and found it very suitable for our growth strategy,” said DY Choi, Senior VP and Managing Director at Dreamtech’s Convergence Division.
Ilan Barak, CTO and co-founder of Sensifree, added, “We’re very proud to be one of the select companies who’ve received the KORIL-RDF grant. This lends further credibility and support to our unique technology. We believe that our work with Dreamtech and KORIL-RDF will be beneficial to our vision to improve patient safety and medical outcome.”
Dr. Tae Hoon Choi, Chief Executive of KORIL-RDF, explained on the selection of the Sensifree-Dreamtech project: “Bio-convergence, an approach that integrates life sciences with additional engineering disciplines, is becoming a new wave in Korea and Israel to overcome the COVID-19 pandemic era. To enhance the cooperation between the two countries, KORIL-RDF is currently planning to promote “Bio-convergence” specifically. The project between Sensifree and Dreamtech well fits our strategy. We were impressed with the use case, the technology, and expect to have a technologically and commercially innovative outcome.”
Jul 10
2018
Cupertino, Calif. (July 10, 2018) – Sensifree, a medical device company developing advanced RF-based hemodynamic monitoring solutions, announces that it has been chosen from thousands of entrants as a winner of the Red Herring Top 100 North America 2018 award. The award recognizes Sensifree as among this year’s most exciting and innovative private technology companies in the North American business region.
“We are honored to be a Red Herring Top 100 winner, which is an important acknowledgment of our innovative solution to continuous blood pressure monitoring without the need for an invasive arterial line,” said Eran Agmon, Sensifree’s co-founder and CEO. “We are well positioned to accelerate development of our first product, a blood pressure monitoring solution for critical care settings, and advance this product toward commercialization.”
Companies considered for the 2018 Red Herring Top North American award were judged by industry experts, insiders and journalists on a wide variety of criteria including financial performance, innovation, business strategy and market penetration.
Red Herring’s editors have been evaluating the world’s startups and tech companies for over two decades. It gives them the ability to see through the industry’s hype, to pick firms that will continue on a trajectory to success. Brands such as Alibaba, Google, Kakao, Skype, Spotify, Twitter and YouTube have all been singled out in Red Herring’s storied history.
“2018’s crop of Top 100 winners has been among our most intriguing yet,” said Red Herring chairman Alex Vieux. “North America has led the way in tech for so many years, and to see such unique, pioneering entrepreneurs and companies here in California, which is in many ways the heartland of the industry, has been a thrilling experience.”
“What has excited me most is to see so many people forging niches in high-tech and cutting-edge sectors,” added Vieux. “Some of the technical wizardry and first-rate business models on show here at the conference has been fantastic to learn about. We believe Sensifree embodies the drive, skill and passion on which tech thrives. Sensifree should be proud of its achievement: the competition was incredibly strong.”
Jun 14
2018
Cupertino, Calif. (June 14, 2018) – Sensifree, a medical device company developing advanced RF-based hemodynamic monitoring solutions, announced today it has been selected as a finalist for Red Herring’s Top 100 North America award, a prestigious list honoring the year’s most promising private technology ventures from the North American business region.
The Red Herring editorial team selected the most innovative companies from a pool of hundreds from across North America. The nominees are evaluated on 20 main quantitative and qualitative criterion, which include disruptive impact, market footprint, proof of concept, financial performance, technology innovation, social value, quality of management, execution of strategy, and integration into their respective industries.
This unique assessment of potential is complemented by a review of the track record and standing of a company, which allows Red Herring to see past the “buzz” and make the list a valuable instrument for discovering and advocating the greatest business opportunities in the industry.
“This year was rewarding, beyond all expectations” said Alex Vieux, publisher and CEO of Red Herring. “There are many great companies generating really innovative and disruptive products in North America. We had a very difficult time narrowing the pool and selecting the finalists. Sensifree shows great promise and therefore deserves to be among the finalists. Now we’re faced with the difficult task of selecting the Top 100 winners of Red Herring North America. We know that the 2018 crop will grow into some amazing companies that are sure to make an impact.”
Finalists for the 2018 edition of the Red Herring 100 North America award are selected based upon their technological innovation, management strength, market size, investor record, customer acquisition, and financial health. During the months leading up to the announcement, Red Herring reviewed over 1200 companies in the telecommunications, security, cloud, software, hardware, biotech, mobile and other industries that completed their submissions to qualify for the award.
Sensifree’s CEO, Eran Agmon, will present at the Red Herring North America Forum in Marina Del Rey, June 18-20, 2018. The Top 100 winners will be announced at a special awards ceremony on the evening of June 20 at the event.
Jan 05
2018
Cupertino, Calif. – (BUSINESS WIRE) – Sensifree, a medical device company developing advanced RF-based hemodynamic monitoring solutions, announces results of a clinical study showing excellent concordance between the signal morphology of its RF based sensor and invasive arterial line, the standard of care for continuous blood pressure monitoring. Clinical data from the study further validate blood pressure extraction and tracking algorithms. Preliminary results demonstrate accurate tracking of systolic and diastolic pressure values.
Jan 23
2017
Neuchâtel (CH), Cupertino, CA (US), and Petach-Tikva (IL); January 23, 2017—Sensifree and CSEM join forces to create a disruptive technology for monitoring blood pressure without using a cuff. Combining CSEM’s expertise in the field of blood pressure monitoring and Sensifree’s novel, RF-based approach will pave the way for the production of a new tool for the highly attractive health wearables market.
Sep 20
2016
Sensifree Ltd. (Cupertino, Calif.) was founded in 2012 and claims to have developed a contact free, electromagnetic sensor that accurately collect a range of continuous biometric data without the need to touch the human body. The Sensifree technology uses RF signal to sense movement in the radial artery wall to track heart rate, and in the future blood pressure. Having taken the pulse digital signal processing is used to extract more information.
May 24
2016
Sensifree Secures $5M in Series A Financing Led by TransLink Capital
Cupertino, CA and Petach-Tikva, Israel, May 24, 2016 — Sensifree, the pioneer in low power, contact free, electromagnetic sensors that accurately collect a range of continuous biometric data without the need to touch the human body, today announced it has completed a $5.0 million Series A round of financing. TransLink Capital led the investment round with participation from existing and new investors, including UMC Capital, a subsidiary of United Microelectronics Corp. (NYSE: UMC) and an undisclosed strategic investor.
Meet The Team
Eran Agmon | CEO & Co-founder
Eran is a veteran of the technology industry, with over 20 years of experience in various companies, both mature?and startups, in which he held executive and senior level positions in corporate development, product strategy?and marketing.
Eran brings with him proven experience in developing new businesses from scratch, with strong?multi disciplinary technical background. Eran holds a B.Sc.EE degree from the Tel-Aviv University.?Prior to founding Sensifree, Eran worked at Gilat Satellite Networks, Camero-Tech and Raysat Antenna Systems.
llan Barak | CTO & Co-founder
Ilan is an expert in microwaves, RF and chip design. With over 35 years of experience in the Israeli hi-tech?industry and more than 20 patents filed by him, Ilan leads the technological innovation in Sensifree.
Ilan holds B.Sc. and M.Sc. degrees in electrical engineering,?both from the Tel-Aviv University. Prior to founding Sensifree, Ilan worked at Gilat Satellite Networks, Intel and Raysat Antenna Systems.
Benny Zeevi, MD?| Managing General Partner, Tel Aviv Venture Partners
Dr. Benny Zeevi is an interventional pediatric cardiologist and leads the fund life science?investments.?He is a prominent figure and deeply involved in?the Israeli life sciences and digital health industries.?Dr. Zeevi is the chairman of the board of several companies and advisor to other companies. Dr. Zeevi holds an MD degree (Magna Cum Laude) from the Sackler?School of Medicine, Tel Aviv University, Israel.
Eric Hsia?| Venture Partner, Translink Capital
Eric leads TransLink?s activities supporting portfolio companies with their customers?and partners, primarily in Greater China. He is interested in companies at the intersection of health and information technology, finance and technology,?and consumer services. Eric is a founder of Eternal?Capital and a private investor, board member, and advisor to public and private technology companies. He earned a B.A. in Economics from Harvard College.
Eran Agmon?|?CEO & Co-founder
Eran is a veteran of the technology industry, with over 20 years of experience in various companies, both mature?and startups, in which he held executive and senior level positions in corporate development, product strategy?and marketing. Eran brings with him proven experience in developing new businesses from scratch, with strong?multi disciplinary technical background. Eran holds a B.Sc.EE degree from the Tel-Aviv University.?Prior to founding Sensifree, Eran worked at Gilat Satellite Networks, Camero-Tech and Raysat Antenna Systems.
llan Barak?|?CTO & Co-founder
Ilan is an expert in microwaves, RF and chip design. With over 35 years of experience in the Israeli hi-tech?industry and more than 20 patents filed by him, Ilan leads the technological innovation in Sensifree.?Ilan holds B.Sc. and M.Sc. degrees in electrical engineering,?both from the Tel-Aviv University. Prior to founding Sensifree, Ilan worked at Gilat Satellite Networks, Intel and Raysat Antenna Systems.
Daniel Sessler, MD?| Medical Advisor
Dr. Sessler is the Michael Cudahy Professor and Chair of the Department of OUTCOMES RESEARCH at the Cleveland Clinic. He is also Director of the OUTCOMES RESEARCH CONSORTIUM: the Consortium is the world?s largest clinical anesthesia research group and publishes a full paper every 3 days. He is an editor for Anesthesiology and serves as a reviewer for more than 50 journals. His grants total $50 million. Dr. Sessler has published more than 700 full research papers which have been cited more than 30,000 times ? making him the world?s most published anesthesiologist. His awards include a Fulbright Fellowship and the ASA Excellence in Research prize.
Arthur Wallace, MD?| Medical Advisor
Dr. Wallace is a professor and vice-chair of anesthesiology and perioperative care at the University of California, San Francisco and Chief of the Anesthesia Service at the Veterans Affairs Medical Center in San Francisco. He completed a B.S. in engineering and applied science with a specialty in electrical engineering at Yale. He then completed an M.D. and Ph.D. at Johns Hopkins Medical School with his Ph.D. in biomedical engineering with research in systems physiology and autonomic control of the vasculature.
Contact Us
Headquarters
21631 Stevens Creek Blvd. Suite B, Cupertino, CA 95014, USA
Tel: +1-669-230-5116
R&D Center
Beit Hapa’amon – HaTa’as St. 20
Kfar Saba, 4442520, Israel.
PO Box 195
Tel: +972-9-745-3930
